| Tiburio Launches from Cydan with $31M to Tackle Pituitary Tumors | Frank Vinluan | 01/03/19 | Boston |
| With $145M Buyout, River Vision’s Plan For Stalled Roche Drug Pays Off | Ben Fidler | 05/08/17 | New York |
| Cydan, NEA’s Orphan Drug Experiment, Pays Off in $200M Vtesse Deal | Ben Fidler | 04/03/17 | Boston |
| scPharmaceuticals Obtains $45,600,000 Series B Financing Round | VentureDeal | 01/05/17 | Boston |
| Iconic Therapeutics Lands $10,000,000 Series C Financing | VentureDeal | 08/10/16 | San Francisco |
| Imara Lands $31,000,000 Series A Round | VentureDeal | 04/15/16 | San Francisco |
| Cydan, NEA’s Orphan Drug Accelerator, Targets Sickle Cell With Startup Imara | Ben Fidler | 04/14/16 | Boston |
| Spero Eyes First Trial, Gets $30M More to Battle Drug-Resistant Bugs | Ben Fidler | 02/02/16 | Boston |
| Spero Therapeutics Receives $30,000,000 New Funding | VentureDeal | 02/02/16 | Boston |
| Iconic Therapeutics Secures $40,000,000 Series C Financing Round | VentureDeal | 01/11/16 | San Francisco |
| East Coast Biotech Roundup: XTuit, Spero, Unum, RNAi Feud & More | Ben Fidler | 06/12/15 | Boston |
| With $30M, Spero Broadens Fight Against Drug-Resistant Bugs | Ben Fidler | 06/08/15 | Boston |
| San Diego Life Sciences Roundup: Thesan, Zogenix, Illumina, and More | Bruce V. Bigelow | 02/28/14 | San Diego |
| Thesan Pharmaceuticals Secures $49,000,000 Series B Financing | VentureDeal | 02/25/14 | San Diego |
| East Coast Life Sciences Roundup: Moderna, Inotek, Roche, & More | Ben Fidler | 10/04/13 | Boston |
| Cydan Secures $10,000,000 New Funding | VentureDeal | 10/01/13 | Boston |
| Naurex Lands $38,000,000 Series B Financing | VentureDeal | 12/17/12 | Detroit Ann Arbor |
| River Vision Development Secures $17,000,000 Series A Round | VentureDeal | 12/13/12 | New York |
| San Diego’s Celladon Extends Round to $53M, Opens European Office | Bruce V. Bigelow | 05/08/12 | San Diego |
| Adimab, ImmunoGen, OvaScience, & More Boston Life Sciences News | Erin Kutz | 04/06/12 | Boston |
| Boston Deals: Funding for FRX, Allocure, Good Start, & FirstBest | Erin Kutz | 04/03/12 | Boston |
| Celladon Raises $43M, Wins Fast-Track Status for Heart Treatment | Bruce V. Bigelow | 02/15/12 | San Diego |
